Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting

被引:11
作者
Becker, RC [1 ]
机构
[1] Univ Massachusetts, Sch Med, UMass Mem Med Ctr, Cardiovasc Thrombosis Res Ctr, Worcester, MA 01655 USA
关键词
heparin-induced thrombocytomis; hiruden; revascularization;
D O I
10.1023/A:1027385304093
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction that is associated with thrombotic events of the venous and arterial circulatory systems stemming from an intense and well-characterized prothrombotic triad of platelet activation, coagulation cascade stimulation and vascular endothelial cell injury. Although heparin (or other sulfated mucopolysaccharide compound) cessation represents a vital first step in management, patients remain susceptible to life-threatening thrombosis for up to several weeks, providing a strong rationale for a 'proactive approach' to care that includes prompt initiation of an alternative anticoagulant strategy throughout the high-risk period. The importance of alternative options for anticoagulation is most evident in clinical situations wherein treatment is a recognized standard of care and prerequisite for an optimal outcome. The following review highlights the use of recombinant hirudin (lepirudin) among patients with suspected HIT requiring precutaneous coronary interventions (PCI) and coronary arterial bypass grafting.
引用
收藏
页码:S59 / S68
页数:10
相关论文
共 29 条
[1]   Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].
Antman, EM .
CIRCULATION, 1996, 94 (05) :911-921
[2]   PLATELET AND FIBRIN DEPOSITION ON CORONARY STENTS IN MINIPIGS - EFFECT OF HIRUDIN VERSUS HEPARIN [J].
BUCHWALD, AB ;
SANDROCK, D ;
UNTERBERG, C ;
EBBECKE, M ;
NEBENDAHL, K ;
LUDERS, S ;
MUNZ, DL ;
WIEGAND, V .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 21 (01) :249-254
[3]   A PILOT TRIAL OF RECOMBINANT DESULFATOHIRUDIN COMPARED WITH HEPARIN IN CONJUNCTION WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI)-5 TRIAL [J].
CANNON, CP ;
MCCABE, CH ;
HENRY, TD ;
SCHWEIGER, MJ ;
GIBSON, RS ;
MUELLER, HS ;
BECKER, RC ;
KLEIMAN, NS ;
HAUGLAND, JM ;
ANDERSON, JL ;
SHARAF, BL ;
EDWARDS, SJ ;
ROGERS, WJ ;
WILLIAMS, DO ;
BRAUNWALD, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) :993-1003
[4]   Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393 [J].
Eriksson, BI ;
Ekman, S ;
Kalebo, P ;
Zachrisson, B ;
Bach, D ;
Close, P .
LANCET, 1996, 347 (9002) :635-639
[5]  
Hafner G, 1996, EUR HEART J, V17, P1207
[6]  
Haycraft JB., 1884, ARCH EXP PATHOL PH, V18, P209, DOI DOI 10.1007/BF01833843
[7]   EFFECTS OF THROMBIN INHIBITION ON THE DEVELOPMENT OF ACUTE PLATELET-THROMBUS DEPOSITION DURING ANGIOPLASTY IN PIGS - HEPARIN VERSUS RECOMBINANT HIRUDIN, A SPECIFIC THROMBIN INHIBITOR [J].
HERAS, M ;
CHESEBRO, JH ;
PENNY, WJ ;
BAILEY, KR ;
BADIMON, L ;
FUSTER, V .
CIRCULATION, 1989, 79 (03) :657-665
[8]   HIRUDIN, HEPARIN, AND PLACEBO DURING DEEP ARTERIAL INJURY IN THE PIG - THE INVIVO ROLE OF THROMBIN IN PLATELET-MEDIATED THROMBOSIS [J].
HERAS, M ;
CHESEBRO, JH ;
WEBSTER, MWI ;
MRUK, JS ;
GRILL, DE ;
PENNY, WJ ;
BOWIE, EJW ;
BADIMON, L ;
FUSTER, V .
CIRCULATION, 1990, 82 (04) :1476-1484
[9]   ANALYSIS OF THE SECONDARY STRUCTURE OF HIRUDIN AND THE MECHANISM OF ITS INTERACTION WITH THROMBIN [J].
KONNO, S ;
FENTON, JW ;
VILLANUEVA, GB .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1988, 267 (01) :158-166
[10]   Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin [J].
Koster, A ;
Kuppe, H ;
Hetzer, R ;
Sodian, R ;
Crystal, GJ ;
Mertzlufft, F .
ANESTHESIOLOGY, 1998, 89 (03) :777-780